You can buy or sell Neuralstem and other stocks, options, ETFs, and crypto commission-free!
Neuralstem, Inc. Common Stock, also called Neuralstem, is a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Read More Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel and proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.
52 Week High
52 Week Low
Markets InsiderMar 22
Neuralstem Reports Year End 2018 Fiscal Results
GERMANTOWN, Md., March 22, 2019 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, today reported its financial results for the year ended December 31, 2018. Financial Results for the Year Ended December 31, 2018 Cash Position and Liquidity: At December 31, 2018, cash and investments was approximately $5.8 million as compared to approximately $11.7 million fo...
Stock Price, News, & Analysis for Neuralstem
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemica...
Available Mar 22, After Hours